I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Instrument under sections 84AF, 84AK, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated 12 May 2014

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health

1 Name of Instrument

 (1) This Instrument is the National Health (Listing of Pharmaceutical                              Benefits) Amendment Instrument 2014 (No. 5).

 (2) This Instrument may also be cited as PB 36 of 2014.

2 Commencement

This Instrument commences on 1 June 2014.

3 Amendment of National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012)

 Schedule 1 amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012).

Schedule 1 Amendments

[1]                Schedule 1, entry for Alendronic acid with colecalciferol in the form Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[2]                Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 5 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[3]                Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 5 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[4]                Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 5 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[5]                Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 5 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[6]                Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 10 mg amlodipine (as besylate) with 10 mg atorvastatin (as calcium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[7]                Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 10 mg amlodipine (as besylate) with 20 mg atorvastatin (as calcium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[8]                Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 10 mg amlodipine (as besylate) with 40 mg atorvastatin (as calcium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[9]                Schedule 1, entry for Amlodipine with Atorvastatin in the form Tablet 10 mg amlodipine (as besylate) with 80 mg atorvastatin (as calcium)

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[10]            Schedule 1, entry for Arginine with carbohydrate in each of the forms: Sachets of oral powder 4 g containing 500 mg arginine, 30 (Arginine 500); and Sachets of oral powder 4 g containing 2 g arginine, 30 (Arginine 2000)

omit from the column headed “Circumstances”: C1458 substitute: C4555

[11]            Schedule 1, after entry for Arginine with carbohydrate in the form Sachets of oral powder 4 g containing 2 g arginine, 30 (Arginine 2000)

insert:

[12]            Schedule 1, entry for Candesartan in each of the forms: Tablet containing candesartan cilexetil 4 mg; Tablet containing candesartan cilexetil 8 mg; Tablet containing candesartan cilexetil 16 mg; and Tablet containing candesartan cilexetil 32 mg

(a)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

(b)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[13]            Schedule 1, entry for Candesartan with Hydrochlorothiazide in the form Tablet containing candesartan cilexetil 16 mg with hydrochlorothiazide 12.5 mg

(a)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

(b)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[14]            Schedule 1, entry for Candesartan with Hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 12.5 mg

(a)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

(b)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[15]            Schedule 1, entry for Candesartan with Hydrochlorothiazide in the form Tablet containing candesartan cilexetil 32 mg with hydrochlorothiazide 25 mg

(a)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

(b)        insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[16]            Schedule 1, entry for Codeine with Paracetamol [Maximum Quantity: 20; Number of Repeats: 0]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[17]            Schedule 1, entry for Codeine with Paracetamol [Maximum Quantity: 60 CN2064; Number of Repeats: 0]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[18]            Schedule 1, entry for Diltiazem in the form Tablet containing diltiazem hydrochloride 60 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[19]            Schedule 1, entry for Enalapril in each of the forms: Tablet containing enalapril maleate 5 mg; and Tablet containing enalapril maleate
10 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[20]            Schedule 1, entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL

(a)        omit from the column headed “Brand”: Epirubicin Actavis 100  substitute: Epirubicin ACT

(b)        omit from the column headed “Responsible Person”: TA substitute: VN

[21]            Schedule 1, entry for Everolimus in each of the forms: Tablet 5 mg; and Tablet 10 mg

insert in numerical order in  the column headed “Circumstances”: C4557

[22]            Schedule 1, entry for Exemestane

substitute:

[23]            Schedule 1, after entry for Fentanyl in the form Transdermal patch 16.8 mg [Brand: Fentanyl Sandoz]

insert:

[24]            Schedule 1, entry for Gemfibrozil

(a)        omit:

(b)        omit:

[25]            Schedule 1, after entry for Glucose Indicator—Blood in the form Test strips, 100 (FreeStyle Optium)

insert in the columns in the order indicated:

[26]            Schedule 1, entry for Lactulose

(a)        omit:

(b)        omit:

(c)        omit:

[27]            Schedule 1, entry for Lamotrigine in the form Tablet 50 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[28]            Schedule 1, entry for Mycophenolic Acid in the form Capsule containing mycophenolate mofetil 250 mg

(a)        omit:

(b)        omit:

[29]            Schedule 1, entry for Mycophenolic Acid in the form Tablet containing mycophenolate mofetil 500 mg

(a)        omit:

(b)        omit:

[30]            Schedule 1, entry for Nandrolone Decanoate

omit from the column headed “Responsible Person”:  MK substitute: AS

[31]            Schedule 1, entry for Oestriol in each of the forms: Pessaries 500 micrograms, 15; and Vaginal cream 1 mg per g, 15 g

omit from the column headed “Responsible Person”:  MK substitute: AS

[32]            Schedule 1, after entry for Phenoxybenzamine in the form Capsule containing phenoxybenzamine hydrochloride 10 mg

insert in the columns in the order indicated:

[33]            Schedule 1, entry for Phenoxybenzamine

omit:

[34]            Schedule 1, entry for Rabeprazole in the form Tablet containing rabeprazole sodium 20 mg (enteric coated) [Maximum Quantity: 30; Number of Repeats: 2]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[35]            Schedule 1, entry for Rabeprazole in the form Tablet containing rabeprazole sodium 20 mg (enteric coated) [Maximum Quantity: 30; Number of Repeats: 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[36]            Schedule 1, entry for Risperidone in the form Tablet 2 mg [Maximum Quantity: 60; Number of Repeats: 2]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[37]            Schedule 1, entry for Risperidone in the form Tablet 2 mg [Maximum Quantity: 60; Number of Repeats: 5]

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[38]            Schedule 1, entry for Risperidone in the form Tablet 3 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

[39]            Schedule 1, after entry for Tamoxifen in the form Tablet 20 mg (as citrate) [Brand: Tamoxifen Sandoz]

insert:

[40]            Schedule 3, after details relevant to Responsible Person code JJ

insert:

[41]            Schedule 3, after details relevant to Responsible Person code VI

insert:

[42]            Schedule 4, Part 1, entry for Arginine with carbohydrate

substitute:

[43]            Schedule 4, Part 1, entry for Everolimus

insert in numerical order following existing text:

[44]            Schedule 4, Part 1, entry for Exemestane

insert in numerical order following existing text:

[45]            Schedule 4, Part 1, entry for Plerixafor [Circumstances Code: 4549]

omit from the column headed “Circumstances and Purposes”:

Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per microlitre on the day of planned collection; OR

substitute:

Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per millilitre or less than 10 million per litre on the day of planned collection; OR

[46]            Schedule 4, Part 1, entry for Plerixafor [Circumstances Code: 4550]

omit from the column headed “Circumstances and Purposes”:

Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per microlitre on the day of planned collection; OR

substitute:

Patient must be undergoing chemotherapy plus G-CSF mobilisation and their peripheral blood CD34+ count is less than 10,000 per millilitre or less than 10 million per litre on the day of planned collection; OR

[47]            Schedule 4, Part 1, after entry for Tamoxifen

insert: